Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma Recruiting Phase 3 Trials for Filgrastim (DB00099)

IndicationStatusPhase
DBCOND0119061 (Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03907488Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaTreatment